PM01183 / PM1183 / Lurbinectedin / Trytamicidin .

Latest Information Update: 09 Dec 2016.

Price : $50 .

At a glance 

         OriginatorPharmaMar .

•            DeveloperFundacion Instituto Valenciano de                                            Oncologia; PharmaMar .
• 
  
• 
  
• Class3-ring heterocyclic compounds; Acetates; Alkaloids; Antineoplastics; Dioxolanes; Indoles; Small molecules
• 
  
• 
  
• Mechanism of ActionAlkylating agents; Apoptosis stimulants; Cell cycle inhibitors
• 
  

• 
  
• Orphan Drug StatusYes - Ovarian cancer
• 
  
• 
  
• 
  
• On Fast trackNo
• 
  
• 
  
• New Molecular EntityYes

Highest Development Phases

                Phase IIIOvarian cancer; Small cell lung cancer. 

• Phase IIBreast cancer; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours.
• 
  
• 
  
• Phase ILeukaemia .
• 
  

Most Recent Events

• 28 Nov 2016Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease) in Japan (IV).
• 
  
• 
  
• 18 Oct 2016PharmaMar completes enrolment in the Phase-III CORAIL trial for Ovarian Cancer (Second-line therapy or greater) in USA (IV) .
• 
  
• 
  
• 10 Oct 2016Efficacy data from a phase II trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016) .